Clinical Trial

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 27, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON Clinicaltrial.gov ID: NCT03849118)
Trial Details
NCT Number NCT06750419
Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 82 participants
Start Date 2024-11-06
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-27